{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:15:27Z","timestamp":1788336927850,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T00:00:00Z","timestamp":1262649600000},"content-version":"vor","delay-in-days":2410,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["beva.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Equine Veterinary Journal"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Reasons for performing study<\/jats:italic>\n                    : Trilostane, a competitive 3\u2010beta hydroxysteroid dehydrogenase inhibitor, has been used successfully to control clinical signs and cortisol excess in canine pituitary dependent hyperadrenocorticism\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Objectives<\/jats:italic>\n                    : Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Methods<\/jats:italic>\n                    : Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4\u20131 mg\/kg (mean 0.5 mg\/kg) trilostane once daily.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    : Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and\/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13\/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 \u00b1 53.0 nmol\/l) and after (130 \u00b1 46.1 nmol\/l) trilostane.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions<\/jats:italic>\n                    : Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Potential relevance<\/jats:italic>\n                    : Trilostane may be a useful therapy for the treatment of ECS. Further work comparing the effects of trilostane and pergolide is warranted.\n                  <\/jats:p>","DOI":"10.2746\/042516403776014271","type":"journal-article","created":{"date-parts":[[2007,4,12]],"date-time":"2007-04-12T19:03:27Z","timestamp":1176404607000},"page":"414-418","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy of trilostane for the treatment of equine Cushing's syndrome"],"prefix":"10.1111","volume":"35","author":[{"given":"C. M.","family":"McGOWAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"NEIGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,5]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"349","article-title":"Diagnosis of pituitary adenoma by using a combined dexamethasone suppression, and TRH stimulation test","volume":"43","author":"Andrews F.M.","year":"1997","journal-title":"Proc. Am. Ass. equine Practnrs."},{"key":"e_1_2_1_3_1","volume-title":"Equine Medicine and Surgery","author":"Beech J.","year":"1999"},{"key":"e_1_2_1_4_1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2460\/ajvr.1985.46.09.1941","article-title":"Hormonal response to thyrotropin\u2010releasing hormone in healthy horses and in horses with pituitary adenoma","volume":"46","author":"Beech J.","year":"1985","journal-title":"Am. J. vet. Res."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0737-0806(99)80111-7"},{"key":"e_1_2_1_6_1","volume-title":"Large Animal Internal Medicine","author":"Dybdal N.L.","year":"1996"},{"key":"e_1_2_1_7_1","volume-title":"Current Therapy in Equine Medicine","author":"Dybdal N.L.","year":"1997"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2460\/javma.1994.204.04.627","article-title":"Diagnostic testing for pituitary pars intermedia dysfunction in horses","volume":"204","author":"Dybdal N.O.","year":"1994","journal-title":"J. Am. vet. med. Ass."},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2460\/javma.1997.211.01.79","article-title":"Results of a combined dexamethasone suppression\/thyrotropin\u2010releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma","volume":"211","author":"Eiler H.","year":"1997","journal-title":"J. Am. vet. med. Ass."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0739-7240(94)90030-2"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0007-1935(05)80084-3"},{"key":"e_1_2_1_12_1","unstructured":"Mantis P. Lamb C.andNeiger R.(2002).Effect of trilostane therapy on adrenal gland size in 13 dogs with pituitary\u2010dependent hyperadrenocorticism: an ultrasonographic study. In:Proceedings of the 9th Meeting of the European Association of Veterinary Diagnostic Imaging.p32."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-123-3-1598"},{"key":"e_1_2_1_14_1","unstructured":"Neiger R.andHurley K.(2001)24\u2010hour cortisol values in dogs with hyperadrenocorticism on trilostane. In:Proceedings of the 44th British Small Animal Veterinary Association Congress.p549."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.150.26.799"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-111-2-559"},{"key":"e_1_2_1_17_1","first-page":"286","article-title":"Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptidine or pergolide","volume":"15","author":"Perkins G.","year":"2001","journal-title":"J. vet. intern. Med."},{"key":"e_1_2_1_18_1","first-page":"154","article-title":"Low\u2010dose pergolide mesylate treatment for equine hypophyseal adenomas (Cushing's syndrome)","volume":"41","author":"Peters D.F.","year":"1995","journal-title":"Proc. Am. Ass. equine Practnrs."},{"key":"e_1_2_1_19_1","first-page":"107","article-title":"Trilostane in the management of Cushing's syndrome","volume":"102","author":"Semple C.G.","year":"1983","journal-title":"Acta Endocrinol."},{"key":"e_1_2_1_20_1","first-page":"22","article-title":"The Michigan Cushing's project","volume":"47","author":"Schott H.C.","year":"2001","journal-title":"Proc. Am. Ass. equine Practnrs."},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-110-3-941"},{"key":"e_1_2_1_22_1","article-title":"Endogenous plasma adrenocorticotrophic hormone before and after therapy with trilostane for pituitary dependent hyperadrenocortiscism","author":"Witt A.L.","year":"2003","journal-title":"Vet. Rec."}],"container-title":["Equine Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.2746%2F042516403776014271","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/pdf\/10.2746\/042516403776014271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:38:17Z","timestamp":1762072697000},"score":1,"resource":{"primary":{"URL":"https:\/\/beva.onlinelibrary.wiley.com\/doi\/10.2746\/042516403776014271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.2746\/042516403776014271"],"URL":"https:\/\/doi.org\/10.2746\/042516403776014271","archive":["Portico"],"relation":{},"ISSN":["0425-1644","2042-3306"],"issn-type":[{"value":"0425-1644","type":"print"},{"value":"2042-3306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]},"assertion":[{"value":"2010-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}